Insulin-like Growth Factor-binding Protein-1 (IGFBP-1)
Use
This test helps identify women who are at high risk for developing preeclampsia. The measurement of Insulin-like Growth Factor-binding Protein-1 (IGFBP-1) in serum can provide important clinical information since its levels are associated with the pathophysiology of preeclampsia. Assessing the serum levels may aid clinicians in early intervention and management strategies.
Special Instructions
Collection must be done carefully, following the specified instructions. Blood should be drawn in a plain red-top tube; a serum gel tube is also acceptable. It's crucial to spin down the sample within one hour of collection and ensure the serum is frozen in a plastic vial before submission.
Limitations
The test is not FDA cleared or approved, indicating it is developed as an Analyte Specific Reagent (ASR) without undergoing full FDA review. The test may also face limitations regarding the accurate prediction of preeclampsia risk. It is important to interpret results within the context of a comprehensive clinical evaluation, as factors such as lab conditions and patient variability might affect results.
New York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 12722-5
- 12722-5
Result Turnaround Time
6-16 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.1 mL
Container
Plastic vial
Collection Instructions
Draw blood in a plain red-top tube(s), serum gel tube is acceptable. Spin down within one hour and send 0.5 mL of serum frozen in a plastic vial.
Causes for Rejection
Warm Reject; Cold Reject; Specimens other than serum
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 48 hours |